The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
about
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.Azole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51)Novel investigational therapies for onychomycosis: an update.Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasisEvaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylaseA complex game of hide and seek: the search for new antifungalsAzole antifungals: 35 years of invasive fungal infection management.New facets of antifungal therapy.Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.Trehalose pathway as an antifungal target.Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs.The antifungal pipeline: a reality check.Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Drugs in Clinical Development for Fungal Infections.Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.Antifungal resistance: current trends and future strategies to combat.Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?New Horizons in Antifungal Therapy.VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.Antifungals discovery: an insight into new strategies to combat antifungal resistance.Coumarin Antifungal Lead Compounds from Millettia thonningii and Their Predicted Mechanism of Action.Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.
P2860
Q35168981-40120301-9DF8-4BC2-A395-987A91061BD0Q35642775-B71CE94E-EC19-4B4F-A52C-C7501EA41D2EQ35893705-4F26E3F0-48FE-4EE7-A00B-E3CAB80CBE26Q35960896-C5BDC8D8-C28C-4927-9B89-069D5C08FE13Q36290706-17FA2EB8-07C7-40EE-8705-F442F376940DQ36366481-D42EB91F-79DB-42B4-B75B-BF7BDAE07D9AQ36571788-88CCD002-5067-4C78-BF08-9A97425E5A53Q36730109-77A76F1D-FAF8-4F13-A809-D10F496E1713Q36910544-6F6BD969-F961-4EC8-8E45-7AA6A3CA15E9Q37344546-200432C7-BA38-4F01-A134-2D5B5F4AA10FQ38406393-FBEBF8AC-E4FD-4B2F-9BDE-652EC3F33A5CQ38797864-121BA366-5257-40CC-875A-8E6F00021253Q38810307-BC20BE46-F37F-4CED-8C04-0033FAE58A3CQ38850003-3DD636DC-F424-4A5A-B2C4-F0A9929135F0Q38910487-B791007C-9A36-4623-8B9E-AE4A176637D1Q39299949-4D2A739E-B923-4445-9B0A-4E8E4DAC552EQ39338332-CF8A6FBF-9911-4C49-ADF6-21524EF5D33EQ40045666-1FFFBE5A-5A4E-4A61-AF51-3092E2ACC39FQ40070714-ED299BEE-D76B-49C6-BE8C-05C580045EA5Q40157268-23ECD3F4-EFA8-4F67-AC45-FDD298EAD4B8Q40412735-83785446-9E45-47FD-B1CC-39A6BFC2ECA2Q41000467-7D99BF6B-C9C7-4190-891A-8E1C26D16D2AQ41632930-2DF48998-EDCE-40A6-8D18-6BA80E130FB3Q47645128-4EE29FD3-CD05-4161-B149-8F3C93E5DDBEQ48149179-FDB16107-8659-4D6E-B4DD-C4E903365271Q50080933-D044269C-D34D-4D4A-8982-F790165989FCQ50122600-5D847AC9-3A6C-402D-9F7D-49A3EA531F6DQ51380847-39894AE5-A891-4547-A10F-6C75118E7017Q55098668-32B08A2C-75FC-462A-9FD9-9AC3E938BB4C
P2860
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@ast
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@en
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@nl
type
label
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@ast
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@en
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@nl
prefLabel
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@ast
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@en
The clinical candidate VT-1161 ...... ails to bind the human enzyme.
@nl
P2093
P2860
P356
P1476
The clinical candidate VT-1161 ...... fails to bind the human enzyme
@en
P2093
E P Garvey
R J Schotzinger
W J Hoekstra
P2860
P304
P356
10.1128/AAC.03707-14
P407
P577
2014-09-15T00:00:00Z